CRIS Current Research Information System

LAMBERTI, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.853
NA - Nord America 3.473
EU - Europa 2.079
SA - Sud America 306
AF - Africa 272
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.994
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.401
VN - Vietnam 2.252
SG - Singapore 1.683
CN - Cina 1.637
IT - Italia 516
HK - Hong Kong 449
DE - Germania 289
KR - Corea 248
SE - Svezia 238
BR - Brasile 217
GB - Regno Unito 212
IN - India 196
FR - Francia 142
NL - Olanda 142
IE - Irlanda 102
RU - Federazione Russa 96
FI - Finlandia 92
CI - Costa d'Avorio 78
JP - Giappone 70
CH - Svizzera 66
TG - Togo 58
ID - Indonesia 50
AR - Argentina 47
BG - Bulgaria 40
ZA - Sudafrica 36
JO - Giordania 34
CA - Canada 33
PH - Filippine 33
AT - Austria 31
TH - Thailandia 30
SC - Seychelles 29
BD - Bangladesh 28
IQ - Iraq 28
MX - Messico 28
TR - Turchia 21
PK - Pakistan 20
NG - Nigeria 19
TW - Taiwan 19
BE - Belgio 17
MA - Marocco 14
PL - Polonia 14
ES - Italia 12
UA - Ucraina 12
CL - Cile 11
EG - Egitto 9
AU - Australia 8
EC - Ecuador 8
EE - Estonia 8
LT - Lituania 8
SA - Arabia Saudita 8
TN - Tunisia 8
VE - Venezuela 7
GR - Grecia 6
PY - Paraguay 6
AZ - Azerbaigian 5
HU - Ungheria 5
KE - Kenya 5
LB - Libano 5
MY - Malesia 5
NP - Nepal 5
AL - Albania 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
HR - Croazia 4
RO - Romania 4
SN - Senegal 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
IL - Israele 3
KG - Kirghizistan 3
KW - Kuwait 3
KZ - Kazakistan 3
LU - Lussemburgo 3
PE - Perù 3
GE - Georgia 2
IR - Iran 2
JM - Giamaica 2
MK - Macedonia 2
MN - Mongolia 2
NI - Nicaragua 2
OM - Oman 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BY - Bielorussia 1
GF - Guiana Francese 1
GM - Gambi 1
GT - Guatemala 1
GY - Guiana 1
HT - Haiti 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
ML - Mali 1
MT - Malta 1
NZ - Nuova Zelanda 1
Totale 12.986
Salva come PNG Salva come JPEG
Città #
Singapore 1.157
Ho Chi Minh City 643
Ashburn 552
Hefei 521
Hanoi 500
Hong Kong 422
San Jose 376
Santa Clara 241
Seoul 232
Fairfield 190
Chandler 185
Beijing 169
Southend 141
Boardman 121
Bologna 115
Dublin 100
Princeton 79
Seattle 79
Abidjan 78
Houston 78
Woodbridge 78
Da Nang 74
Dong Ket 74
Los Angeles 72
Helsinki 69
Lauterbourg 69
Wilmington 69
Council Bluffs 64
Haiphong 62
Bern 61
Lomé 58
Tokyo 57
Buffalo 49
New York 47
Bengaluru 46
Biên Hòa 46
Cambridge 46
Milan 44
Shanghai 40
Dallas 39
Sofia 39
Frankfurt am Main 38
Quận Bình Thạnh 38
Redondo Beach 38
Amman 33
Jakarta 31
Turin 31
Guangzhou 30
Munich 30
Ninh Bình 29
Hải Dương 28
Can Tho 27
São Paulo 27
Ann Arbor 24
Chicago 24
Falkenstein 24
Ha Long 24
Thái Nguyên 24
Hyderabad 21
Nuremberg 21
Amsterdam 20
Berlin 20
Johannesburg 19
Vicenza 19
Redmond 18
Tongling 18
Abeokuta 17
Bắc Ninh 17
Lappeenranta 17
London 17
Nanjing 16
Oldenburg 16
Orem 16
Thái Bình 16
Des Moines 15
Jinan 15
Rome 15
Westminster 15
Brooklyn 14
Florence 14
Vienna 14
Wuhan 14
Yubileyny 14
Atlanta 13
Hangzhou 13
Montreal 13
Phoenix 13
Zhengzhou 13
Chengdu 12
Tianjin 12
Vũng Tàu 12
Điện Bàn 12
Baghdad 11
Breda 11
Brussels 11
Bắc Giang 11
Mexico City 11
San Diego 11
Shenyang 11
Thành Phố Bà Rịa 11
Totale 8.301
Salva come PNG Salva come JPEG
Nome #
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 896
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option? 234
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 232
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 199
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 197
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review 191
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 190
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 184
Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors 183
Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas 178
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC 173
The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? 171
Treatment of advanced gastro‐entero‐pancreatic neuro‐ endocrine tumors: A systematic review and network meta‐analysis of phase iii randomized controlled trials 170
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors 166
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12CMutant Non-Small Cell Lung Cancer 165
Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients 165
[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time? 161
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 160
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 159
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 157
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 157
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 155
An Update on Appendiceal Neuroendocrine Tumors 153
Appendiceal goblet cell carcinoma has marginal advantages from perioperative chemotherapy: a population-based study with an entropy balancing analysis 149
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 147
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer 146
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 145
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels 140
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor 136
Landscape and future perspectives of immunotherapy in neuroendocrine neoplasia 136
Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading? 136
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease 134
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 133
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 132
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers 130
Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review 129
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 129
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 126
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study 126
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) 125
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 123
The role of clinical and molecular factors in low-grade gliomas: What is their impact on survival? 123
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors 123
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 122
Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors 122
Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes 120
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 119
The functioning side of the pancreas: a review on insulinomas 119
Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma 118
Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications 118
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 118
Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population-based analysis 117
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC 116
Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study 116
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET) 113
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 113
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges 112
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study 111
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances 108
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 106
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients 105
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 105
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives 105
Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs 104
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 103
Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study From the French Group of Endocrine Tumors (GTE) 100
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 99
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study 98
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? 98
Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis 97
β1600 Q.Clear Digital Reconstruction of [68Ga]Ga-DOTANOC PET/CT Improves Image Quality in NET Patients 94
The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis 85
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 84
Gastric neuroendocrine neoplasms 83
Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study 82
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 80
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 80
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 78
Challenges and future perspectives for the use of temozolomide in the treatment of SCLC 77
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 76
Non-small-cell lung cancer: how to manage RET-positive disease 74
Cutaneous Scapular Lesion in an Elderly Woman 74
Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis 73
Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management 73
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 73
BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: A case report and review of the literature 72
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) 70
ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS) 68
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 67
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status 66
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 65
Should we lose hope in adjuvant therapy for neuroendocrine tumors?—In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit 63
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 61
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 60
Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors 60
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1-2 cm 59
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 58
Reply to ‘The need for a better classification system for gastric neoplasms’ 57
Non-small-cell lung cancer: how to manage EGFR-mutated disease 55
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 52
Totale 12.565
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.370
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.370
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021222 0 0 0 0 0 0 0 0 0 40 19 163
2021/2022706 12 11 28 30 77 34 15 62 47 63 222 105
2022/20231.229 79 129 50 97 80 87 59 92 244 70 109 133
2023/2024490 36 60 34 40 37 110 24 67 14 32 20 16
2024/20252.682 114 250 264 192 360 139 212 104 37 179 231 600
2025/20267.289 1.602 890 594 556 590 315 692 377 1.241 432 0 0
Totale 13.373